Cargando…

Clinical Value of Tissue Transglutaminase Antibodies in Celiac Patients over a Long Term Follow-Up

Introduction & Aim: Anti-tissue transglutaminase antibody (tTGA) titer is used during the follow-up of celiac patients to evaluate gluten-free diet (GFD) responsiveness. However, no clear data are available on this issue. The aim of this study was to evaluate tTGA significance during celiac dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Farina, Elisa, Roncoroni, Leda, Lombardo, Vincenza, Scricciolo, Alice, Vecchi, Maurizio, Doneda, Luisa, Elli, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465060/
https://www.ncbi.nlm.nih.gov/pubmed/34578935
http://dx.doi.org/10.3390/nu13093057
_version_ 1784572774620069888
author Farina, Elisa
Roncoroni, Leda
Lombardo, Vincenza
Scricciolo, Alice
Vecchi, Maurizio
Doneda, Luisa
Elli, Luca
author_facet Farina, Elisa
Roncoroni, Leda
Lombardo, Vincenza
Scricciolo, Alice
Vecchi, Maurizio
Doneda, Luisa
Elli, Luca
author_sort Farina, Elisa
collection PubMed
description Introduction & Aim: Anti-tissue transglutaminase antibody (tTGA) titer is used during the follow-up of celiac patients to evaluate gluten-free diet (GFD) responsiveness. However, no clear data are available on this issue. The aim of this study was to evaluate tTGA significance during celiac disease (CD) monitoring. Methods: From January 2017 to January 2020, consecutive CD patients on a GFD with persistent positive tTGA were enrolled. Antibody titres were evaluated on a yearly basis from CD diagnosis to the last follow-up. Urinary gluten detection tests, duodenal histology and capsule enteroscopy (CE) were performed. A tTGA-positive cohort was compared with a control group composed of 212 treated CD patients with negative tTGA. Results: 65 patients (12% males, median age at enrollment and CD diagnosis, 37 (14–86) and 31 (1–76), respectively, median follow up 4 (1–26) years) presented with positive tTGA during follow-up. Overall, the tTGA titres were 3 (1–79) fold increased (ULN). Three different tTGA trends were recognized: (I) 36 (55%) patients with a progressive titres decrease; (II) 16 (25%) patients with a fluctuating behavior; (III) 13 (20%) patients with a steady state or increased titres. tTGA+ patients did not present with different clinical and demographic parameters. Duodenal atrophy was present in 10% vs. 36% of the tTGA positive vs. negative group (p < 0.005), respectively. Gluten detection results were positive in 3 (8%) cases, all in the III group. In tTGA+ patients, CE did not identify any CD-related complications. Conclusions: tTGA positivity during CD follow up did not present a relevant clinical significance without association with autoimmune comorbidities and mucosal damage.
format Online
Article
Text
id pubmed-8465060
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84650602021-09-27 Clinical Value of Tissue Transglutaminase Antibodies in Celiac Patients over a Long Term Follow-Up Farina, Elisa Roncoroni, Leda Lombardo, Vincenza Scricciolo, Alice Vecchi, Maurizio Doneda, Luisa Elli, Luca Nutrients Article Introduction & Aim: Anti-tissue transglutaminase antibody (tTGA) titer is used during the follow-up of celiac patients to evaluate gluten-free diet (GFD) responsiveness. However, no clear data are available on this issue. The aim of this study was to evaluate tTGA significance during celiac disease (CD) monitoring. Methods: From January 2017 to January 2020, consecutive CD patients on a GFD with persistent positive tTGA were enrolled. Antibody titres were evaluated on a yearly basis from CD diagnosis to the last follow-up. Urinary gluten detection tests, duodenal histology and capsule enteroscopy (CE) were performed. A tTGA-positive cohort was compared with a control group composed of 212 treated CD patients with negative tTGA. Results: 65 patients (12% males, median age at enrollment and CD diagnosis, 37 (14–86) and 31 (1–76), respectively, median follow up 4 (1–26) years) presented with positive tTGA during follow-up. Overall, the tTGA titres were 3 (1–79) fold increased (ULN). Three different tTGA trends were recognized: (I) 36 (55%) patients with a progressive titres decrease; (II) 16 (25%) patients with a fluctuating behavior; (III) 13 (20%) patients with a steady state or increased titres. tTGA+ patients did not present with different clinical and demographic parameters. Duodenal atrophy was present in 10% vs. 36% of the tTGA positive vs. negative group (p < 0.005), respectively. Gluten detection results were positive in 3 (8%) cases, all in the III group. In tTGA+ patients, CE did not identify any CD-related complications. Conclusions: tTGA positivity during CD follow up did not present a relevant clinical significance without association with autoimmune comorbidities and mucosal damage. MDPI 2021-08-31 /pmc/articles/PMC8465060/ /pubmed/34578935 http://dx.doi.org/10.3390/nu13093057 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Farina, Elisa
Roncoroni, Leda
Lombardo, Vincenza
Scricciolo, Alice
Vecchi, Maurizio
Doneda, Luisa
Elli, Luca
Clinical Value of Tissue Transglutaminase Antibodies in Celiac Patients over a Long Term Follow-Up
title Clinical Value of Tissue Transglutaminase Antibodies in Celiac Patients over a Long Term Follow-Up
title_full Clinical Value of Tissue Transglutaminase Antibodies in Celiac Patients over a Long Term Follow-Up
title_fullStr Clinical Value of Tissue Transglutaminase Antibodies in Celiac Patients over a Long Term Follow-Up
title_full_unstemmed Clinical Value of Tissue Transglutaminase Antibodies in Celiac Patients over a Long Term Follow-Up
title_short Clinical Value of Tissue Transglutaminase Antibodies in Celiac Patients over a Long Term Follow-Up
title_sort clinical value of tissue transglutaminase antibodies in celiac patients over a long term follow-up
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465060/
https://www.ncbi.nlm.nih.gov/pubmed/34578935
http://dx.doi.org/10.3390/nu13093057
work_keys_str_mv AT farinaelisa clinicalvalueoftissuetransglutaminaseantibodiesinceliacpatientsoveralongtermfollowup
AT roncoronileda clinicalvalueoftissuetransglutaminaseantibodiesinceliacpatientsoveralongtermfollowup
AT lombardovincenza clinicalvalueoftissuetransglutaminaseantibodiesinceliacpatientsoveralongtermfollowup
AT scriccioloalice clinicalvalueoftissuetransglutaminaseantibodiesinceliacpatientsoveralongtermfollowup
AT vecchimaurizio clinicalvalueoftissuetransglutaminaseantibodiesinceliacpatientsoveralongtermfollowup
AT donedaluisa clinicalvalueoftissuetransglutaminaseantibodiesinceliacpatientsoveralongtermfollowup
AT elliluca clinicalvalueoftissuetransglutaminaseantibodiesinceliacpatientsoveralongtermfollowup